L-Dopa response to Cortical Dysfunctions, health related quality of life and Fatigue Severity in Idiopathic Parkinson’s disease

Amara Gul1, Javed Yousaf2

ABSTRACT

Objectives: To determine (i) levodopa (L-Dopa) responsiveness on cortical functions, health related quality of life and fatigue severity (ii) relationship between cortical functions, health related quality of life and fatigue severity post L-Dopa treatment of patients with idiopathic Parkinson’s Disease (I-PD).

Methods: Participants included 50 patients diagnosed with I-PD who were attending Civil and Bahawal Victoria Hospital, Bahawalpur, Pakistan during May 2016 to July 2017 and 50 healthy individuals (HI) took part in the study. Participants completed Cortical Function Assessment, Parkinson’s Disease Questionnaire and Fatigue Severity Scale. Patients were tested twice on these measures: pre and post- L-Dopa treatment.

Results: Patients with I-PD showed cortical functioning deficits, deteriorated health related quality of life and experience of severe fatigue, in contrast with HI. There was significant improvement in cortical functioning and quality of life while reduction in fatigue severity was observed after three months of L-Dopa medication in I-PD patients. Higher cortical functioning deficits correlated with deteriorated health related quality of life and severe fatigue. Cortical functioning was a significant predictor of health related quality of life and fatigue severity.

Conclusion: L-Dopa is an effective treatment for cortical dysfunctions, health related quality of life and fatigue in I-PD. Cortical functioning is a significant marker of quality of life and fatigue in patients with I-PD.

KEYWORDS: Parkinson’s Disease, Health-related quality of life, Cognition, Chronic Fatigue.
contribute to cognitive deficits. Levodopa (L-Dopa) is an effective initial dopaminergic treatment for improvement of PD symptoms. In Pakistan, PD patients are given L-dopa as a mono-therapy or with combination of other pharmacological agents such as benserzide, anticholinergics etc. A recent study with Pakistani population showed high prevalence of cognitive deficits in patients with PD. Few studies have shown L-dopa beneficial effects on motor function, alertness, cognitive and neuropsychological performance of patients with PD.

There is a missing link in previous literature about L-dopa response to cortical functioning, health related quality of life and fatigue severity in patients with I-PD. Therefore, the present study was designed to examine:
1. Effectiveness of L-Dopa on cortical functioning, health related quality of life and fatigue severity in patients with I-PD.
2. Relationship between cortical functioning, health’s related quality of life and fatigue severity in I-PD patients.

It was hypothesized:
1. I-PD patients would show deteriorated cortical functioning, declined health related quality of life and experience of severe fatigue in contrast with HI.
2. Compared with baseline performance, patients with I-PD would show improved cortical functioning, quality of life and reduced severity of fatigue post L-Dopa treatment.
3. Cortical functioning deficits would correlate with lesser quality of life and greater fatigue severity.
4. Cortical functioning would significantly predict quality of life and fatigue severity.

METHODS

Fifty patients diagnosed with I-PD at Civil and Bahawal Victoria Hospital, Bahawalpur, Pakistan during May 2016 to July 2017 and 50 healthy individuals (HI) participated in the study. All participants were screened for:
1. Dementia using The Rowland Universal Dementia Assessment Scale, score below 23/30 reflects dementia.
2. Depression through Geriatric Depression Scale- short form (score>5).

Inclusion criterion for patients was as follows:
1. Diagnosis of I-PD.
2. Stable on L-Dopa doses for at least 3 months.
3. Not taking any dopamine agonist, antidepressants, anticholinergic medication.

4. No present complaints or history of any psychiatric disorder.
5. No present illness or history of neurological disorder except PD.

Cortical Function Assessment (CFA) was used to assess cortical functions: sensory extinction, dictation, naming, writing, repetition, drawing, and stereognosis. It is a simple, bedside, 10-item clinical assessment. The completion time is approximately 10 minutes. Total score range is 0-10. Lower scores show cortical function deficits. The test has good psychometric characteristics.

Parkinson’s Disease Questionnaire (PDQ) was used to assess health related quality of life in PD patients. It is a 39 item questionnaire to examine eight dimensions of functioning: emotional well-being, activities of daily living, mobility, social support, stigma, communication, cognition, bodily discomfort on 4 point response categories (Total score range= 0-156). Higher score shows deteriorated quality of life. The test is sensitive to evaluate PD related dysfunctions.

Fatigue Severity Scale (FSS) was used to measure chronic fatigue. It is a 9-item scale scored on 7-point response categories (1=strongly disagree to 7= strongly agree). Mean score on items is used as an index of fatigue severity. Higher score shows greater fatigue severity.

Procedure: The study was approved by board of studies of The Islamia University of Bahawalpur. After obtaining informed consent from HI, patients and their caregivers, a trained psychologist administered psychological testing. Participants and psychologist were both blinded to objectives of the study. All participants completed CFA, PDQ and FSS. HI has single testing session whereas patients had two testing sessions. First session was conducted at the time of I-PD diagnosis. Second session was conducted after at least three months of L-dopa treatment. Testing on all mentioned measures were completely randomized across patients to avoid practice effects.

Statistical Analyses: Repeated measures analysis of variance (ANOVA) was conducted with CFA scores 3 (controls vs. patient’s pretreatment vs. patient’s post-treatment) as within subjects factor. Separate ANOVA was conducted with scores on FSS as within subjects repeated factor 3 (controls vs. patient’s pretreatment vs. patient’s post-treatment). ANOVA was conducted with scores on PDQ as within subject repeated factor 3 (controls vs.
patient’s pretreatment vs. patient’s post-treatment). Scores on subscales of PDQ 8 (emotional well-being vs. activities of daily living vs. mobility vs. social support vs. stigma vs. communication vs. cognition vs. body discomfort: within subjects) x Group-3 (controls vs. patient’s pretreatment vs. patient’s post-treatment: between subjects) were analyzed through repeated measures ANOVA. Bivariate correlations will be used to analyze association between post-treatment scores on CFA, FSS and PDQ. Separate regression analysis was conducted to assess CFA scores (independent variable) as predictor of performance on PDQ and FSS (dependent variables) post L-Dopa treatment.

|                      | M±SD    | 95% CI Lower bound | 95% CI Upper bound |
|----------------------|---------|--------------------|--------------------|
| **Cortical function assessment** |         |                    |                    |
| I-PDP pretreatment   | 2.82±0.69 | 2.62               | 3.01               |
| I-PDP post-treatment | 6.36±0.82 | 6.12               | 6.59               |
| HI                   | 6.88±0.47 | 9.54               | 9.81               |
| **Fatigue severity scale** |         |                    |                    |
| I-PDP pretreatment   | 6.02±0.65 | 5.83               | 6.20               |
| I-PDP post-treatment | 4.14±0.45 | 4.01               | 4.26               |
| HI                   | 1.14±0.35 | 1.04               | 1.24               |
| **Parkinson’s disease questionnaire** |         |                    |                    |
| I-PDP pretreatment   | 132.92±12.57 | 129.34          | 136.49             |
| I-PDP post-treatment | 86.36±8.58  | 83.92              | 88.79              |
| HI                   | 7.02±2.63   | 6.27               | 7.77               |
| **Emotional-well-being** |         |                    |                    |
| I-PDP pretreatment   | 22.56±0.92  | 22.33              | 22.79              |
| I-PDP post-treatment | 18.58±0.92  | 18.35              | 18.81              |
| HI                   | 0.76±0.55    | 0.53               | 0.99               |
| **Activities of daily living** |         |                    |                    |
| I-PDP pretreatment   | 22.46±0.90  | 22.32              | 22.68              |
| I-PDP post-treatment | 18.54±0.90  | 18.31              | 18.76              |
| HI                   | 0.84±0.58    | 0.61               | 1.06               |
| **Mobility**         |          |                    |                    |
| I-PDP pretreatment   | 37.16±1.62  | 36.81              | 37.50              |
| I-PDP post-treatment | 30.34±1.22  | 29.99              | 30.68              |
| HI                   | 0.80±0.69    | 0.45               | 1.14               |
| **Social support**   |          |                    |                    |
| I-PDP pretreatment   | 8.48±1.97   | 8.10               | 8.85               |
| I-PDP post-treatment | 3.30±1.11   | 2.92               | 3.67               |
| HI                   | 0.98±0.62    | 0.60               | 1.35               |
| **Stigma**           |          |                    |                    |
| I-PDP pretreatment   | 12.44±2.11  | 11.97              | 12.90              |
| I-PDP post-treatment | 4.30±1.79   | 3.83               | 4.76               |
| HI                   | 0.82±0.71    | 0.35               | 1.28               |
| **Communication**    |          |                    |                    |
| I-PDP pretreatment   | 8.72±2.00   | 8.33               | 9.10               |
| I-PDP post-treatment | 3.38±1.14   | 2.99               | 3.76               |
| HI                   | 1.02±0.65    | 0.63               | 1.40               |
| **Cognition**        |          |                    |                    |
| I-PDP pretreatment   | 12.48±2.14  | 12.02              | 12.93              |
| I-PDP post-treatment | 4.50±1.65   | 4.04               | 4.95               |
| HI                   | 0.82±0.71    | 0.36               | 1.27               |
| **Body discomfort**  |          |                    |                    |
| I-PDP pretreatment   | 8.62±2.08   | 8.21               | 9.02               |
| I-PDP post-treatment | 3.42±1.24   | 3.01               | 3.82               |
| HI                   | 0.98±0.62    | 0.57               | 1.38               |

Note: Read CI: confidence interval, M±SD: Mean ± Standard deviation, HI: Healthy individuals (n=50), I-PDP: Idiopathic Parkinson’s disease Patients (n=50).
RESULTS

Participants had age range between 45 to 65 years. There was no significant difference on age between both groups I-PDP (M± SD 56±5.76) HI (M± SD 57.12±5.09) t (49)=1.02, p=0.30. The ratio of male and female was 50% in each group (25:25). Disease duration (years) for I-PDP was M± SD 3.52±0.81 and L-dose daily (mg) was M± SD 486.80±54.73. There were significant within subject differences on cortical functioning F (2, 98)= 1174.33, p<0.001, ηp2=0.96, quality of life F(2, 98)=4949.96, p<0.001, ηp2=.99, and FSSF (2, 98)=1028.81, p<0.001, ηp2=0.95. Patients with I-PD showed cortical functioning deficits, deteriorated quality of life and fatigue severity in contrast with HI. Post-treatment assessment showed improvement in cortical functioning, quality of life and reduced fatigue severity. Repeated measures ANOVA to assess differences between groups on subscales of PDQ showed significant main effects of PDQ F (7, 147)=11689.77, p<0.001, ηp2=0.98, Group-F (2, 147)= 2546.90, p<0.001, ηp2=0.97 and interaction between PDQ x Group-F (14, 147)=5037.01, p<0.001, ηp2=0.97 (Table-I). This result revealed that in contrast with HI, I-PD patients showed deterioration in all areas of quality of life while post-treatment scores showed significant improvement in emotional well-being, activities of daily living, mobility, social support, stigma, communication, cognition, and body discomfort. Post-treatment scores on CFA were inversely correlated with scores on FSS (r=-.51, p<0.001) and PDQ (r=-.80, p<0.001) in patients with I-PD. Regression analysis showed cortical functioning as significant predictor of fatigue severity R2=.27, F(1, 49)=17.73, p<0.001, β=-.51, t=-4.21, p<0.001 and quality of life R2=.64, F(1, 49)=87.56, p<0.001, β=-.80, t=-9.35, p<0.001 in patients with I-PD post L-Dopa treatment.

DISCUSSION

There were few important results.  
1. Patients with I-PD had cortical functioning deficits, deteriorated health related quality of life and fatigue severity in contrast with HI. 
2. After three months of L-Dopa treatment, there was significant improvement in cortical functioning and health related quality of life in I-PD patients. Reduction in fatigue severity was also observed in response to L-Dopa therapy in patients with I-PD. 
3. Cortical functioning was negatively correlated with quality of life and fatigue severity. 
4. Cortical functioning was a significant predictor of fatigue severity and quality of life in I-PD patients. 

Presence of cognitive deficits in patients with PD have been well-documented in previous studies in Pakistani and Western population.4-6 To be best of to our knowledge, there are no studies which examined cortical functions in this patient group. Thus, results of the present study highlighted cortical function deficits in patients with I-PD. Cortical functioning deficits in patients with I-PD have several pathological factors such as increased levels of [11C](R)-PK11195 in cortical/subcortical regions, susceptibility of cortical/subcortical gray matter development of proteinaceous inclusion bodies starting from brain stem bulging to cerebral cortex weakening limbic, autonomic and motor systems, constant presence of neurotoxin as nigral Glutathione transerase activity and total glutathione deficiency as a result of overutilization in response to oxidative stress, loss of corticocortical projection neurons in motor cortex, and dopamine loss.2,5 These pathological features contribute to cognitive deficits in patients with PD.

Previous studies with PD patients not only showed that cognitive decline had greater impact on quality of life rather severity of cognitive decline contributed to poor quality of life.15,16 Correlation analysis in the present study showed that higher cortical functioning deficits were associated with deteriorated health related quality of life and experience of severe fatigue in patients with I-PD. Cortical functioning was significant predictor of fatigue severity and health related quality of life in I-PD patients. These results are consistent with previous findings of deteriorated quality of life with cognitive decline in such patients. Whilst existent studies in literature have not assessed relationship between cortical functioning, health related quality of life and fatigue severity, thus the present finding is an addition to the literature.

Scarce data have shown that three months treatment of L-dopa is effective in reducing cognitive impairment in PD patients but studies have not assessed efficacy of L-dopa on cortical functions. Result of the present study showed that L-Dopa can bring positive changes in cortical functioning, quality of life and experience of fatigue in patients with I-PD. This finding is consistent with previous studies showing improvement in non-motor symptoms, for instance memory problems in PD patients.8,9 Findings of the current study have implications in better patient care and rehabilitation. Cortical functioning must be assessed at initial stages of treatment in I-PD patients to prevent...
This study highlighted cortical functioning as a marker of quality of life and fatigue severity in patients with I-PD.

Limitations: Long term effects of L-Dopa on cortical functioning, quality of life and fatigue must be studied which constitute a limitation of the present study since the possibility that long-term use of L-Dopa might have adverse effects on these variables. Future studies must compare impacts of short term and long term L-Dopa therapy on cortical functioning, quality of life and fatigue in I-PD patients.

Declaration of Interest: Authors have no conflicts of interests, and the work was not supported by or funded by any drug company.

Grant Support & Financial Disclosures: None.

REFERENCES

1. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway R G, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384-386. doi: 10.1212/01. wnl.0000247740.47667.03.

2. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, et al. In vivo imaging of microglial activation with [11C] (R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis. 2006;21(2):404-412. doi: 10.1016/j.nbd.2005.08.002.

3. Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna). 2003;110(5):517-536. doi: 10.1007/s00702-002-0808-2.

4. Fitzmaurice PS, Ang L, Gutman M, Rajput AH, Furukawa Y, Kish SJ. Nigral glutathione deficiency is not specific for idiopathic Parkinson’s disease. Mov Disord. 2003;18(9):969-976. doi: 10.1002/mds.10486.

5. Halliday GM, Macdonald V, Henderson JM. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson’s disease. Brain. 2005;128(Pt 10):2272-2280. doi: 10.1093/brain/awh596.

6. Khealani BA, Baig SM. Clinical spectrum of Parkinson’s disease from Pakistan. Singapore Med J. 2006;47(12):1075-1079.

7. Saad S, Nomani AZ, Badshah M, Afzal A. Frequency of non-motor symptoms in Parkinson disease: experience from Pakistan. Pak J Neurol Sci. 2017;12(1):8-15. http://ecommons.aku.edu/pjns/vol12/iss1/3.

8. Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson’s disease. Neurosci Biobehav Rev. 2006;30(1):1-23. doi: 10.1016/j.neubiorev.2005.03.024.

9. Molloy SA, Rowan EN, O’Brien JT, McKeith IG, Wesnes K, Burn DJ. Effect of levodopa on cognitive function in Parkinson’s disease with and without dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2006;77(12):1323-1328. doi:10.1136/jnnp.2006.098079.

10. Storey JE, Rowland JT, Basic D, Conforti DA, Dickson HG. The Rowland Universal Dementia Assessment Scale (RUDAS): a multicultural cognitive assessment scale. Int Psychogeriatr. 2004;16(1):13-31.

11. Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. Clin Gerontol. 1986;5:165-173. doi: 10.1300/J018v05n01_09.

12. Herst LD, Voss C, Waldman J. Cortical function assessment in the elderly. Neuropsychiatry Clin Neurosci. 1989;2:385-390. doi:10.1176/jnp.2.4.385.

13. Jenkinson C, Peto V. Self-reported functioning and well-being in patients with Parkinson’s disease. Comparison of the short-form health survey (SF-36) and the Parkinson’s disease questionnaire (PDQ-39). Age Ageing. 1995;24:505-509.

14. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121–1123.

15. Lawson RA, Yarnall AJ, Duncan GW, Breen DP, Khoo TK, Williams-Gray CH, et al. Cognitive decline and quality of life in incident Parkinson’s disease: The role of attention. Parkinsonism Relat Disord. 2016;27:47-53. doi:10.1016/j.parkreldis.2016.04.009.

16. Lawson RA, Yarnall AJ, Duncan GW, Khoo TK, Breen DP, Barker RA, et al. Severity of mild cognitive impairment in early Parkinson’s disease contributes to poorer quality of life. Parkinsonism Relat Disord. 2014;20(10):1071-1075. doi: 10.1016/j.parkreldis.2014.07.004.

Author’s Contribution:

AG: Conceived the study, designed, analyzed data, manuscript writing.

JY: Did literature review, collected data.